Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunovant (IMVT)
NASDAQ:IMVT
Holding IMVT?
Track your performance easily
IMVT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$24.61 - $45.58
Previous Close$25.22
Volume1.01M
Average Volume (3M)890.59K
Market Cap
$3.70B
Enterprise Value$3.23B
Total Cash (Recent Filing)$472.94M
Total Debt (Recent Filing)$47.00K
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Feb 12, 2025EPS Estimate
-$0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.21
Shares Outstanding146,784,639
10 Day Avg. Volume1,090,797
30 Day Avg. Volume890,591
Standard Deviation0.24
R-Squared0.02
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)8.24
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-10.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-9.48
Forecast
1Y Price Target
$50.50Price Target Upside92.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Immunovant News
PremiumCompany Announcements
Immunovant’s Strategic Advances in Autoimmune Therapies
Bulls Say, Bears Say
Bulls Say
Clinical TrialsImmunovant is advancing with a pivotal study in difficult-to-treat rheumatoid arthritis, positioning IMVT-1402 as a potentially better asset for RA.
Indication ExpansionIMVT continues to advance development of ‘1402 with five INDs now cleared, including unveiling of indication expansion and registrational plans into RA.
Market PositionImmunovant has a potential edge over JNJ as its deeper IgG reduction profile may confer benefits and its dosing method (subcutaneous) is advantageous compared to JNJ's IV method.
Bears Say
EarningsThere is a small timeline push for the Ph3 TED readout to the second half of 2025 due to slower than expected enrollment, which has resulted in a slight tweak in the price objective.
Industry ChallengesHigh KOL interest will be balanced by headwinds from the lack of infrastructure for Graves' trials.
Market SentimentThe short interest for the company stands at 20.3% of the float.
---
Ownership Overview
2.61% Insiders
14.53% Mutual Funds
24.73% Other Institutional Investors
49.84% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMVT FAQ
What was Immunovant’s price range in the past 12 months?
Immunovant lowest stock price was $24.61 and its highest was $45.58 in the past 12 months.
What is Immunovant’s market cap?
Currently, no data Available
When is Immunovant’s upcoming earnings report date?
Immunovant’s upcoming earnings report date is Feb 12, 2025 which is in 83 days.
How were Immunovant’s earnings last quarter?
Immunovant released its earnings results on Nov 07, 2024. The company reported -$0.653 earnings per share for the quarter, missing the consensus estimate of -$0.589 by -$0.064.
Is Immunovant overvalued?
According to Wall Street analysts Immunovant’s price is currently Undervalued.
Does Immunovant pay dividends?
Immunovant does not currently pay dividends.
What is Immunovant’s EPS estimate?
Immunovant’s EPS estimate is -$0.73.
How many shares outstanding does Immunovant have?
Immunovant has 146,784,640 shares outstanding.
What happened to Immunovant’s price movement after its last earnings report?
Immunovant reported an EPS of -$0.653 in its last earnings report, missing expectations of -$0.589. Following the earnings report the stock price went down -4.742%.
Which hedge fund is a major shareholder of Immunovant?
Among the largest hedge funds holding Immunovant’s share is Viking Global Investors LP. It holds Immunovant’s shares valued at 66M.
---
Immunovant Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.50 (92.97% Upside)
$50.50 (92.97% Upside)
Blogger Sentiment
Bullish
IMVT Sentiment 80%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 3.6%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.42%
12-Months-Change
Fundamentals
Return on Equity
-92.17%
Trailing 12-Months
Asset Growth
76.57%
Trailing 12-Months
Company Description
Immunovant
Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.
---
IMVT Stock 12 Month Forecast
Average Price Target
$50.50
▲(92.97% Upside)
Technical Analysis
Best Analysts Covering IMVT
1 Year
1 Year Success Rate
12/19 ratings generated profit
1 Year Average Return
+84.99%
reiterated a buy rating 15 days ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 63.16% of your transactions generating a profit, with an average return of +84.99% per trade.
---